The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: HIV peptides. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Innovation in Pharmaceuticals: HIV peptides

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

HIV peptides is a key innovation area in pharmaceuticals

HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. HIV proteins or peptides are very immunogenic, and when utilised as experimental immunogens, they can elicit strong cellular and humoral immune reactions. A piece of an HIV protein, an epitope from an HIV protein, or a mixture of several HIV proteins or fragments of them can all act as the antigenic polypeptide and produce an immune response. These can serve as an important component of a vaccine.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of HIV peptides.

Key players in HIV peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to HIV peptides

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Johnson & Johnson 200 Unlock Company Profile
CareGroup 159 Unlock Company Profile
International AIDS Vaccine Initiative 79 Unlock Company Profile
AECOM 79 Unlock Company Profile
Solon Eiendom 72 Unlock Company Profile
GSK 64 Unlock Company Profile
Esteve Pharmaceuticals 62 Unlock Company Profile
Altimmune 56 Unlock Company Profile
Mymetics 50 Unlock Company Profile
Children's Medical Center 50 Unlock Company Profile
Fundacion IrsiCaixa 47 Unlock Company Profile
Pfizer 47 Unlock Company Profile
Inovio Pharmaceuticals 45 Unlock Company Profile
US Department of Health and Human Services 41 Unlock Company Profile
Mitsubishi Chemical Group 40 Unlock Company Profile
Curevac 40 Unlock Company Profile
U.S. Department of Defense 37 Unlock Company Profile
AGC 37 Unlock Company Profile
Mount Sinai Health System 34 Unlock Company Profile
United States Of America 33 Unlock Company Profile
Triad National Security 32 Unlock Company Profile
Academia Sinica 31 Unlock Company Profile
Centre National de la Recherche Scientifique 31 Unlock Company Profile
SEEK Group 31 Unlock Company Profile
American Gene Technologies International 29 Unlock Company Profile
Providence St. Joseph Health 23 Unlock Company Profile
Merck & Co 22 Unlock Company Profile
EpitoGenesis 20 Unlock Company Profile
Henry M. Jackson Foundation for the Advancement of Military Medicine 16 Unlock Company Profile
Globeimmune 15 Unlock Company Profile
Minka Therapeutics 14 Unlock Company Profile
US Government 14 Unlock Company Profile
Sanofi 14 Unlock Company Profile
Calder Biosciences 13 Unlock Company Profile
Novo Nordisk Foundation 13 Unlock Company Profile
Compagnie Merieux Alliance 13 Unlock Company Profile
Mayo Clinic 12 Unlock Company Profile
Grifols 12 Unlock Company Profile
Los Alamos National Security 12 Unlock Company Profile
United States Army Reserve 12 Unlock Company Profile
Thermo Fisher Scientific 12 Unlock Company Profile
UAB Research Foundation 12 Unlock Company Profile
ICREA 12 Unlock Company Profile
Mupharma 11 Unlock Company Profile
I'rom Group 11 Unlock Company Profile
Gilead Sciences 11 Unlock Company Profile
Profectus BioSciences 11 Unlock Company Profile
Precigen 11 Unlock Company Profile
Japan Science and Technology Agency 9 Unlock Company Profile
Life Sciences Research Partners VZW 9 Unlock Company Profile

Source: GlobalData Patent Analytics

Johnson & Johnson is the leading patent filer in HIV peptides. Johnson & Johnson researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious diseases, cardiovascular and metabolic diseases, consumer products in oral care, baby care, beauty, over the counter (OTC) medicines, women’s health and wound care categories, and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. CareGroup and International AIDS Vaccine Initiative are the other key patent filers in HIV peptides.

In terms of application diversity, Novo Nordisk Foundation is the top company, followed by Minka Therapeutics and GSK. By means of geographic reach, Pfizer holds the top position, while SEEK Group and Profectus BioSciences stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.